TwinStrand Biosciences Says Delaware Court Entered Final Judgment Awarding More Than $245.2M Against Guardant Health, Orders 6% Royalty On 11 Products Through Patent Expiration March 15, 2033

Loading news article.

TwinStrand Biosciences Says Delaware Court Entered Final Judgment Awarding More Than $245.2M Against Guardant Health, Orders 6% Royalty On 11 Products Through Patent Expiration March 15, 2033 | WAPE

TwinStrand Biosciences Says Delaware Court Entered Final Judgment Awarding More Than $245.2M Against Guardant Health, Orders 6% Royalty On 11 Products Through Patent Expiration March 15, 2033

Article summary

Related companies

Comments —